Reports Q2 revenue $344M, consensus $321.77M. “Second quarter sales were on target, given the seasonal nature of Covid. I am pleased with the progress our U.S. commercial team has made to get new contracts in place for fall 2023. We are on track to deliver 2023 sales between $6 billion to $8 billion, depending on Covid vaccination rates in the U.S. Our late-stage clinical pipeline is firing on all cylinders with four infectious disease vaccines in Phase 3, including RSV which was recently submitted to regulators for approval. Our individualized neoantigen therapy is now in Phase 3 for melanoma and our lead rare disease program for PA is in dose confirmation. We believe that all these products should launch in 2024, 2025 or 2026, and we are continuing to invest in scaling Moderna to bring forward an unprecedented number of innovative mRNA medicines for patients,” said Stephane Bancel, CEO of Moderna, earlier this morning.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRNA:
- Deutsche downgrades Moderna to Hold on low revenue visibility
- Moderna downgraded to Hold from Buy at Deutsche Bank
- Moderna (NASDAQ:MRNA) Expects Upbeat COVID-19 Vaccine Sales for 2023; Late Stage Pipeline Impresses
- Moderna director sells $1.81M in common stock
- William Blair to hold a webinar on initiation of coverage
Questions or Comments about the article? Write to editor@tipranks.com